ID

31567

Description

A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00642018

Lien

https://clinicaltrials.gov/show/NCT00642018

Mots-clés

Versions (1)
  1. 05/09/2018 05/09/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

5 septembre 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Prostate Cancer NCT00642018

Anglais

Eligibility Prostate Cancer NCT00642018

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
histologically or cytologically confirmed adenocarcinoma of the prostate which is metastatic and/or unresectable
Description

Adenocarcinoma of the prostate metastatic | Adenocarcinoma of prostate unresectable

Type de données

boolean

Alias
UMLS CUI [1]
C0862636
UMLS CUI [2,1]
C0007112
UMLS CUI [2,2]
C1519810
hormone refractory prostate cancer defined as progressive based by documented 2 increase psa values over a previous reference value.
Description

Hormone refractory prostate cancer Progressive | Raised prostate specific antigen Quantity

Type de données

boolean

Alias
UMLS CUI [1,1]
C1328504
UMLS CUI [1,2]
C0205329
UMLS CUI [2,1]
C0178415
UMLS CUI [2,2]
C1265611
ecog status 0-2
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
adequate hematological functions, liver and renal functions
Description

Hematologic function | Liver function | Renal function

Type de données

boolean

Alias
UMLS CUI [1]
C0221130
UMLS CUI [2]
C0232741
UMLS CUI [3]
C0232804
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
known hypersensitivity to docetaxel or taxane therapy
Description

Hypersensitivity Docetaxel | Hypersensitivity Taxane

Type de données

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0246415
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0215136
documented central nervous system or leptomeningeal metastasis at time of study entry
Description

CNS metastases | Metastatic Malignant Neoplasm to the Leptomeninges

Type de données

boolean

Alias
UMLS CUI [1]
C0686377
UMLS CUI [2]
C1704231
had prior treatment with chemotherapy, bone seeking radionucleides in past 6 weeks prior to enrollment, or radiotherapy involving more than 25% of marrow producing area.
Description

Prior Chemotherapy | Bone-seeking Radioisotope | Therapeutic radiology procedure Bone Marrow Percentage

Type de données

boolean

Alias
UMLS CUI [1]
C1514457
UMLS CUI [2]
C2985504
UMLS CUI [3,1]
C1522449
UMLS CUI [3,2]
C0005953
UMLS CUI [3,3]
C0439165
evidence of painful and/or destructive bone metastases for which radiation therapy, biophosphonates or boneseeking radionucleides are necessary.
Description

Secondary malignant neoplasm of bone Painful | Secondary malignant neoplasm of bone Destruction | Therapeutic radiology procedure Required | Diphosphonates Required | Bone-seeking Radioisotope Required

Type de données

boolean

Alias
UMLS CUI [1,1]
C0153690
UMLS CUI [1,2]
C0030193
UMLS CUI [2,1]
C0153690
UMLS CUI [2,2]
C1948029
UMLS CUI [3,1]
C1522449
UMLS CUI [3,2]
C1514873
UMLS CUI [4,1]
C0012544
UMLS CUI [4,2]
C1514873
UMLS CUI [5,1]
C2985504
UMLS CUI [5,2]
C1514873
have received treatment in the last 30 day with a drug which has not received regulatory approval for any indication at the time of study entry.
Description

Drugs, Non-Prescription

Type de données

boolean

Alias
UMLS CUI [1]
C0013231
Retour au début de la page

Similar models

Eligibility Prostate Cancer NCT00642018

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Adenocarcinoma of the prostate metastatic | Adenocarcinoma of prostate unresectable
Item
histologically or cytologically confirmed adenocarcinoma of the prostate which is metastatic and/or unresectable
boolean
C0862636 (UMLS CUI [1])
C0007112 (UMLS CUI [2,1])
C1519810 (UMLS CUI [2,2])
Hormone refractory prostate cancer Progressive | Raised prostate specific antigen Quantity
Item
hormone refractory prostate cancer defined as progressive based by documented 2 increase psa values over a previous reference value.
boolean
C1328504 (UMLS CUI [1,1])
C0205329 (UMLS CUI [1,2])
C0178415 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
ECOG performance status
Item
ecog status 0-2
boolean
C1520224 (UMLS CUI [1])
Hematologic function | Liver function | Renal function
Item
adequate hematological functions, liver and renal functions
boolean
C0221130 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Hypersensitivity Docetaxel | Hypersensitivity Taxane
Item
known hypersensitivity to docetaxel or taxane therapy
boolean
C0020517 (UMLS CUI [1,1])
C0246415 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0215136 (UMLS CUI [2,2])
CNS metastases | Metastatic Malignant Neoplasm to the Leptomeninges
Item
documented central nervous system or leptomeningeal metastasis at time of study entry
boolean
C0686377 (UMLS CUI [1])
C1704231 (UMLS CUI [2])
Prior Chemotherapy | Bone-seeking Radioisotope | Therapeutic radiology procedure Bone Marrow Percentage
Item
had prior treatment with chemotherapy, bone seeking radionucleides in past 6 weeks prior to enrollment, or radiotherapy involving more than 25% of marrow producing area.
boolean
C1514457 (UMLS CUI [1])
C2985504 (UMLS CUI [2])
C1522449 (UMLS CUI [3,1])
C0005953 (UMLS CUI [3,2])
C0439165 (UMLS CUI [3,3])
Secondary malignant neoplasm of bone Painful | Secondary malignant neoplasm of bone Destruction | Therapeutic radiology procedure Required | Diphosphonates Required | Bone-seeking Radioisotope Required
Item
evidence of painful and/or destructive bone metastases for which radiation therapy, biophosphonates or boneseeking radionucleides are necessary.
boolean
C0153690 (UMLS CUI [1,1])
C0030193 (UMLS CUI [1,2])
C0153690 (UMLS CUI [2,1])
C1948029 (UMLS CUI [2,2])
C1522449 (UMLS CUI [3,1])
C1514873 (UMLS CUI [3,2])
C0012544 (UMLS CUI [4,1])
C1514873 (UMLS CUI [4,2])
C2985504 (UMLS CUI [5,1])
C1514873 (UMLS CUI [5,2])
Drugs, Non-Prescription
Item
have received treatment in the last 30 day with a drug which has not received regulatory approval for any indication at the time of study entry.
boolean
C0013231 (UMLS CUI [1])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial